INTRODUCTION {#S0001}
============

Resveratrol (trans--3, 4', 5--trihydroxystilbene, C~14~H~12~O~3~) is a plant--derived polyphenolic phytoalexin produced in response to environmental stress such as vicissitudes in climate, exposure to ozone, sunlight and heavy metals, and infection by pathogenic microorganisms. Resveratrol exists in both cis-- and trans-- stereoisomeric forms, the predominant trans-- isomer is the biologically active one \[[@CIT0001], [@CIT0002], [@CIT0003]\]. Exposure to heat and ultraviolet radiation can cause trans--resveratrol to isomerize to the cis--resveratrol. It is primarily found in the skin of grapes as well as in other fruits and plants, such as raspberries, blueberries, mulberries, Scots pine, Eastern white pine, and knotweed \[[@CIT0001], [@CIT0004]\].

It is speculated that uptake of resveratrol by red wine consumption could be behind the so--called French paradox -- whereby the French population, in spite of a rather fatty diet, has a lower incidence of cardiovascular disease \[[@CIT0001]\]. Resveratrol is also produced by chemical and biotechnological synthesis and sold as a nutritional supplement. It is well absorbed upon oral ingestion and metabolized to sulfate and glucuronate \[[@CIT0001], [@CIT0002]\].

Resveratrol has been reported do have a wide range of effects beneficial for health, including cardioprotective, neuroprotective, and immunomodulatory function as well as improving insulin sensitivity, but in relation to prostatic diseases, the following ones are the most interesting: anticancer -- resveratrol has been reported to have antiproliferative and proapoptotic effects on prostate cancer cell lines LNCaP, DU--145, and PC--3; it also potentiates the effect of ionizing radiation and chemotherapeutic agents; potential chemopreventive properties; antiinflammatory and antioxidant functions, which may be useful in treatment of prostate inflammation; and also play a role in chemoprevention, as a positive correlation between prostatitis and prostate cancer risk has been reported \[[@CIT0005], [@CIT0006]\].

Prostate cancer (PCa), being one of the most common malignancies and a major cause of cancer--related death in men, is a considerable health problem, especially in ageing populations, since it is typically diagnosed in men over the age of 50 \[[@CIT0006], [@CIT0007]\]. All these, together with its long latency, make PCa an attractive target for chemopreventive interventions \[[@CIT0004], [@CIT0006]\]. There is also a considerable amount of epidemiological data suggesting that certain nutritional factors may influence PCa occurrence \[[@CIT0006], [@CIT0008]\]. Consequently, several PCa risk reduction studies were conducted, but only in two of them -- PCPT (finasteride) and REDUCE (dutasteride) -- a reduction of PCa incidence was observed. The most important endpoint -- the reduction of mortality, however, was not reached in either of them \[[@CIT0009]\]. This may be partially due to the slow natural course of the disease, which would require an ideal observation period of around 20 years. In this paper, recently published research articles on the application of resveratrol in prostate diseases have been reviewed in order to shed light on the evidence justifying its application in prevention and treatment of prostate diseases.

Mechanism of action {#S20002}
-------------------

Resveratrol induces a broad range of effects on cell phenotype. Numerous studies have reported resveratrol to cause cell growth inhibition, modulation of cell cycle, induction of apoptosis in many different cell lines, including PCa ones \[[@CIT0002], [@CIT0010]--[@CIT0045]\], and induction of differentiation in certain cell types \[[@CIT0027], [@CIT0046]--[@CIT0049]\]. All these are important in cancer treatment and are exerted by modulating a complex range of cellular processes, including: receptor function, transduction pathways, and transcription factor activity. The detailed description of all the documented resveratrol mechanisms of action would exceed this paper. Apart from these, resveratrol has been reported to exhibit other properties that may be useful in cancer treatment: inhibition of tumor invasion and angiogenesis as well as increase of radiosensitivity and chemosensitivity.

The expression of matrix metalloproteases (MMPs) correlates with tumor invasion and metastasis, which make them attractive pharmaceutical targets in cancer treatment \[[@CIT0050]\]. Resveratrol reduced the expression of MMP--2 and MMP--9 in certain cell lines \[[@CIT0051]--[@CIT0055]\] and decreased the level of vascular epithelial growth factor (VEGF), a protein crucial for angiogenesis and maintaining tumor growth, thus inhibiting angiogenesis \[[@CIT0056]--[@CIT0060]\].

Another interesting property of resveratrol is its ability to increase prostate cancer cell lines sensitivity to ionizing radiation, which has a potential for clinical application in combination with radiotherapy -- an important treatment in PCa \[[@CIT0017], [@CIT0019], [@CIT0020], [@CIT0043]\].

Resveratrol has also been shown to sensitize human cancer cell lines, including prostate carcinoma, to such chemotherapeutic agents as doxorubicin, cytarabine, actinomycin D, taxol, and methotrexate by down--regulating survivin expression and increasing apoptosis \[[@CIT0061]\]. Inflammation has been proven to be a significant factor in the initiation/progression stages of cancer development by inducing oxidative damage and promoting cell growth \[[@CIT0062], [@CIT0063]\]. Cyclooxygenase--2 (COX--2) catalyzes the conversion of free arachidonic acid to prostaglandins, which can stimulate cell proliferation, promote angiogenesis, and suppress apoptosis all of which promote malignancy \[[@CIT0064]--[@CIT0066]\]. Resveratrol expresses anti--inflammatory activity by directly inhibiting COX--2 activity and suppressing NFκB by up--regulating MKP5 \[[@CIT0044], [@CIT0067]\].

Review of current studies {#S20003}
-------------------------

Resveratrol and its mechanisms of action have been intensively investigated and a large amount of evidence suggesting that it may be a promising molecule in both PCa treatment and prevention has been collected. MEDLINE search (keywords "prostate resveratrol") resulted in 39 research papers published since 2007 -- the results of which are presented in [Table 1](#T0001){ref-type="table"}. Surprisingly, a considerable number of *in vitro* and a few animal model experiments have been performed, with lack of human clinical trials. There are currently no published demonstrations of therapeutic or protective effects of resveratrol in appropriately designed clinical trials \[[@CIT0064]\]. Web page <http://www.clinicaltrials>.org reported five ongoing trials of resveratrol in cancer, but none in prostate disease. The results of several resveratrol pharmacokinetics and metabolism studies in humans, however, have already been published and despite good absorption upon oral administration, poor bioavailability of unchanged resveratrol indicates that it would be difficult to achieve concentrations proven to be effective in *in vitro* studies \[[@CIT0068], [@CIT0069]\]. Additionally, a study by Klink et al., indicates that resveratrol may actually worsen the survival in certain prostate cancer xenograft models \[[@CIT0070]\].

###### 

Studies on resveratrol in prostate diseases published in years 2007--2012

  Ref. no.     Model used                                                                                Observed effects and mechanism
  ------------ ----------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@CIT0072]   SV--40 Tag rats                                                                           suppressed prostate cancer development
  [@CIT0073]   TRAMP mice                                                                                suppressed tumor growth in vivo
  [@CIT0012]   PC--3, TRAMP--C2 cell lines TRAMP mice                                                    reduced cell proliferation; reduced prostate cancer in vivo; inhibits Hedgehog signaling
  [@CIT0013]   PTEN--CaP8 cell line prostate--specific PTEN--KO mice                                     reduces cell proliferation, induces apoptosis; decreased prostatic adenocarcinoma in vivo
  [@CIT0014]   COS7, LNCaP cell lines TRAP rats                                                          induces apoptosis through androgen receptor down--regulation; suppressed tumur growth in vivo
  [@CIT0070]   mouse xenograft model of prostate cancer (LNCaP and LAPC--4)                              worsens survival with LAPC--4 tumors, no difference with LNCaP tumours
  [@CIT0071]   mouse xenograft model of prostate cancer                                                  inhibited tumor growth, metastasis and angiogenesis
  [@CIT0015]   LNCaP cell line mouse xenograft model of prostate cancer                                  reduces cell proliferation *in vitro*; delayed tumor growth in vivo
  [@CIT0016]   PC--3M--MM2 cell line mouse xenograft model of prostate cancer                            reduced cell viability, migration and invasiveness inhibited the tumor growth, decreased the incidence and number of metastases
  [@CIT0017]   LAPC4, CWR22, LNCaP, PC--3, DU--145 cell lines mouse xenograft model of prostate cancer   reduces cell proliferation *in vitro*; no effect observed in vivo
  [@CIT0018]   PC--3 cell line                                                                           enhanced irradiation--induced apoptosis
  [@CIT0019]   PC--3, DU--145 cell lines                                                                 enhanced irradiation--induced apoptosis by up--regulation of the expression of perforin and granzyme B
  [@CIT0020]   PC--3, 22RV1, PNT1A cell lines                                                            enhanced irradiation--induced apoptosis, arrests cell cycle
  [@CIT0021]   DU--145 cell line                                                                         enhanced irradiation--induced apoptosis
  [@CIT0022]   LNCaP cell line                                                                           inhibits the function of the androgen receptor
  [@CIT0023]   LNCaP cell line                                                                           inhibition of androgen--promoted growth, inhibition of androgen receptor transcriptional activity, effect synergistic with flutamide
  [@CIT0024]   LNCaP cell line                                                                           inhibition of androgen receptor transcriptional activity
  [@CIT0025]   LNCaP, PC--3 cell lines                                                                   decreased the post--translational androgen receptor level
  [@CIT0026]   LNCaP, PC--3 cell lines                                                                   decreased androgen receptor and estrogen receptor alpha protein levels
  [@CIT0027]   C4--2, LNCaP cell lines                                                                   stimulates PTEN expression through androgen receptor inhibition, inhibits EGFR phosphorylation decreasing AKT phosphorylation
  [@CIT0028]   LNCaP cell line                                                                           reduces cell proliferation, induces apoptosis; inhibited the phosphorylation of PI3K, AKT and mTOR
  [@CIT0029]   LNCaP cell line                                                                           induced cell cycle arrest and apoptosis
  [@CIT0030]   LNCaP cell line                                                                           reduces cell proliferation, induces apoptosis; sensitized cells to TRAIL
  [@CIT0031]   LNCaP, DU--145 cell lines                                                                 down--regulated oncogenic microRNAs and up--regulated tumor suppressor microRNAs
  [@CIT0032]   LNCaP, DU--145 cell lines                                                                 induces apoptosis; restores p53--signaling pathways
  [@CIT0033]   LNCaP, PC--3 cell lines                                                                   reduces cell proliferation, induces apoptosis; inhibits NFκB specific binding to DNA
  [@CIT0034]   LNCaP, PC--3, DU--145 cell lines                                                          induces apoptosis, SOCS--3 reduced apoptosis in resveratrol--treated cells
  [@CIT0035]   LAPC4, LNCaP, PC--3, DU--145 cell lines                                                   anti--inflammatory activity by up--regulation of MKP5
  [@CIT0036]   PZ--HPV--7, LNCaP, PC--3 cell lines                                                       induced cell cycle arrest, reduced cell proliferation
  [@CIT0037]   C4--2, LNCaP cell lines                                                                   induces apoptosis
  [@CIT0038]   PC--3 cell line                                                                           inhibition of cell proliferation, down--regulation of expression of CAV1, IGF2, NR2F1, and PLAU genes, suppressed secretion of the urokinase plasminogen activator
  [@CIT0002]   PC--3, DU--145 cell lines                                                                 reduces cell proliferation; trans-- isoform more active than cis--
  [@CIT0039]   PC--3, DU--145 cell lines                                                                 sensitized cells to TRAIL, Fas, TNFalpha
  [@CIT0040]   PC--3, DU--145 cell lines                                                                 down--regulated the expression of Bcl--2, Bcl--X(L) and survivin and upregulated the expression of Bax, Bak, PUMA, Noxa, Bim, TRAIL--R1/DR4 and TRAIL--R2/DR5
  [@CIT0041]   C4--2B, PC--3, DU--145, LNCaP, RWPE--1 cell lines                                         reduces cell proliferation; modulation of SIRT1/S6K signaling
  [@CIT0042]   22Rv1, PC--3, DU--145 cell lines                                                          synergistic with Ad▵? adenovirus, increases apoptosis
  [@CIT0043]   CWR22Rv1 cell line                                                                        reduced cell proliferation
  [@CIT0044]   RWPE--1, WPE1--NA22, WPE1--NB14, WPE1--NB26 cell lines                                    induced cell cycle arrest
  [@CIT0045]   ALVA--41, PC--3 cell lines                                                                reduces cell proliferation, induces apoptosis; synergy with casein kinase 2 inhibition

Among 38 research papers on resveratrol in prostate diseases published between 2007 and 2012, 35 were performed on cell lines and nine on *in vivo* models (five transgenic models of PCa development and five PCa xenografts). Seven studies concentrated on the role of androgen receptor and four on enhancement of radiosensitivity ([Table 1](#T0001){ref-type="table"}). A short characteristic of PCa cell lines most commonly used in experiments listed in [Table 1](#T0001){ref-type="table"} -- their androgen sensitivity, p53 and PTEN (proteins important in mechanism of action of resveratrol in PCa cells) are presented in [Table 2](#T0002){ref-type="table"}. TRAMP, TRAP, and SV--40 Tag are transgenic animal models of PCa development -- animals programmed to develop prostate cancer -- were used to assess potential chemopreventive properties of resveratrol.

###### 

A short characteristic of PCa cell lines

  Cell line   androgen sensitivity        p53          PTEN
  ----------- --------------------------- ------------ ------------
  PC--3       AR--negative                mutant       mutant
  DU--145     AR--negative                mutant       wild--type
  C4--2B      androgen independent        wild--type   mutant
  LNCaP       broad steroid specificity   wild--type   mutant
  LAPC--4     wild--type                  mutant       wild--type
  CWR22rv1    androgen independent        mutant       wild--type

CONCLUSIONS {#S0004}
===========

The anti--cancer potential of resveratrol has been well documented in many *in vitro* and *in vivo* studies. Down--regulation of androgen receptor and synergy with flutamide, as well as enhancement of radiosensitivity are the most interesting properties in treatment of prostate cancer.

Resveratrol has displayed a potential as prostate cancer chemoprevention in both *in vitro* and animal model studies.

Resveratrol is well--tolerated, but an optimal dose has not yet been determined.

There are no results from human clinical trials on therapeutic effects of resveratrol in prostate diseases. Despite promising results from many studies, published evidence is not strong enough to justify chronic administration of resveratrol to humans.
